{"nctId":"NCT01248065","briefTitle":"Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma","startDateStruct":{"date":"2011-04"},"conditions":["Asthma"],"count":408,"armGroups":[{"label":"Ciclesonide + placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Ciclesonide"]},{"label":"Ciclesonide + Vitamin D","type":"EXPERIMENTAL","interventionNames":["Drug: Vitamin D3","Drug: Ciclesonide"]}],"interventions":[{"name":"Vitamin D3","otherNames":[]},{"name":"Ciclesonide","otherNames":["Alvesco®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women 18 years of age and older\n* Physician-diagnosed asthma for at least previous 12 months\n* Asthma confirmed by: (a) β-agonist reversibility of forced expiratory volume in 1 second (FEV1) ≥12 % following 180 mcg (4 puffs) levalbuterol at visit 1 OR (b) methacholine provocative concentration causing a 20% fall in FEV1 (PC20) ≤ 8 mg/ml if not receiving an inhaled corticosteroid or ≤ 16 mg/ml if receiving an inhaled corticosteroid at visit 2. Source documentation for PC20 from an AsthmaNet methacholine challenge completed within 6 months of visit 2 will be accepted.\n* Stable asthma controller therapy (inhaled corticosteroid or leukotriene modifier only) dose for past 2 weeks\n* FEV1 ≥ 50% of predicted at visit 1\n* Vitamin D level of less than 30 ng/ml at visit 0\n* Experienced no more than one treatment failure in the VIDA run-in or oral corticosteroid (OCS) response periods on previous enrollments\n* For women of childbearing potential: not pregnant, non-lactating, and agree to practice an adequate birth control method for the duration of the study\n\nExclusion Criteria:\n\n* Taking vitamin D supplements containing \\> 1000 IU/day of vitamin D\n* Taking \\>2500 mg/day calcium supplements\n* Chronic oral corticosteroid therapy\n* Chronic inhaled corticosteroid therapy \\> 1,000 mcg of fluticasone daily or the equivalent\n* History of physician-diagnosed nephrolithiasis\n* Use of concomitant medications that alter vitamin D metabolism - phenytoin, phenobarbital, cardiac glycosides; or absorption - orlistat, cholestyramine, colestipol; or those that interfere with study endpoints\n* Impaired renal function (GFR \\< 30 ml/min)\n* Asthma exacerbation within past 4 weeks requiring systemic corticosteroids\n* Respiratory tract infection within past 4 weeks\n* Chronic diseases (other than asthma)\n* History of cigarette smoking within the past 1 year or \\> 10 pack years total\n* Serum calcium greater than 10.2 mg/dl on entry\n* Urine calcium/creatinine ratio greater than 0.37 (urinary Ca and Creat in mg)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment Failure","description":"Treatment failure is a well-defined asthma outcome reflecting overall asthma control that has been used previously in multiple clinical trials. Treatment failure as defined in the current proposal and prior trials is consistent with the American Thoracic Society (ATS)/European Respiratory Society(ERS) definition of a moderate exacerbation - a deterioration in symptoms and/or lung function with increased rescue bronchodilator use that lasts 2 days or more. The percentages of participants experiencing a treatment failure are Kaplan-Meier estimates of failure rate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Lung Function Change From Baseline","description":"FEV1 (liters) and methacholine PC20 will be evaluated. Changes are measured as 28 weeks minus baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":null},{"groupId":"OG001","value":"-0.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Exacerbations","description":"Outcome defined as number of exacerbations per person-year.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":null},{"groupId":"OG001","value":"0.26","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":207},"commonTop":["Diseases of the respiratory system","Symptoms, signs, and ill-defined conditions","Diseases of the musculoskeletal system and connective tissue","Injury and poisoning","Diseases of the nervous system and sense organs"]}}}